OmniAb (OABI) Earnings Date & Reports

Key Takeaways

• OmniAb reported third quarter 2026 revenue of roughly $4.0 million, an 81.4% year-over-year increase from $2.2 million, exceeding consensus estimates.
• GAAP (Generally Accepted Accounting Principles) net loss per share came in at approximately $0.12, essentially in line with analyst expectations.
• Management raised its full-year 2026 revenue guidance to a range of $35 million to $39 million, up from the prior $32 million to $36 million outlook.
• Nine-month revenue reached $31.8 million, compared with $10.3 million in the prior-year period, driven primarily by milestone revenue.
• Growth was fueled by higher service revenue, expansion of the xPloration platform, and strong instrument sales across antibody and ion channel programs.
• The company ended the quarter with 34 active clinical programs and approved products, plus more than $3 billion in total contracted potential milestones.
• For additional detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Interested readers can also explore Trending AI Robots for additional AI-driven market insights.

Earnings Context and Why It Matters

OmniAb, Inc. (NASDAQ: OABI) licenses discovery research technology to pharmaceutical and biotech companies to support the development of next-generation therapeutics. Because the company's revenue is heavily milestone-driven, quarterly results can be uneven, making each report an important checkpoint on partner-program progression rather than a simple measure of recurring sales. The third quarter 2026 print carries particular weight because it follows a sharp, front-end-loaded surge in milestone revenue earlier in the year. Investors were watching whether service momentum and the commercial rollout of the xPloration platform could sustain growth after a period of milestone-driven variability, and whether management would adjust its full-year outlook in response to the stronger top line.

Reported Results

For the third quarter ended September 30, 2026, OmniAb reported revenue of approximately $4.0 million, up from $2.2 million in the same period last year, an increase of 81.4%. The result beat consensus estimates of roughly $3.56 million. The top-line growth was driven primarily by higher service revenue and xPloration revenue, supported by work on both antibody and ion channel programs and by strong instrument sales.

On the bottom line, the company posted a GAAP net loss of about $0.12 per share, essentially matching consensus expectations. Total costs and operating expenses were approximately $20.4 million, unchanged from the prior-year period, as lower research and development (R&D) spending was partially offset by higher general and administrative (G&A) costs and increased cost of sales tied to instrument placements.

For the nine-month period, revenue totaled $31.8 million, versus $10.3 million a year earlier, reflecting the milestone-heavy nature of 2026 results. Management also raised its full-year revenue guidance to between $35 million and $39 million, up from the previous $32 million to $36 million range, signaling continued confidence in the company's commercial momentum.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like OmniAb across the biotech and life-sciences landscape, the AI Screener offers a structured way to identify and monitor relevant opportunities.

Market Reaction and Investor Sentiment

Sentiment around OmniAb heading into the report was shaped by the company's earlier 2026 momentum, including a second-quarter earnings beat and a licensing agreement with Eli Lilly for an ion channel program worth up to $370 million. The third-quarter revenue beat and upward guidance revision reinforced that narrative, with management emphasizing progress across its partner pipeline, expanding technology offerings, and the commercial rollout of the xPloration platform. Investors have continued to weigh the company's recurring-revenue potential against its ongoing net losses, with attention focused on whether service and instrument-led growth can reduce the historical reliance on lumpy milestone payments.

Forward Outlook and Key Factors to Monitor

Following the third-quarter report, investors will likely focus on whether OmniAb can convert its expanding installed base into durable, recurring revenue. Management expects xPloration revenue of $2 million to $3 million in 2026, with that figure projected to double in 2027 and again in 2028 as consumables, software licenses, and service contracts scale.

Milestone and royalty activity remains a central driver. The company reported more than $3 billion in total contracted potential milestones, with an average royalty rate of approximately 3.4%, and roughly $340 million in remaining potential milestones tied to its active clinical programs. The number of clinical entrants and downstream regulatory events among partners will therefore be key swing factors for future quarters.

Finally, investors should watch cost discipline, the pace of new partnership signings, and the adoption of newer discovery technologies. Service revenue from the Eli Lilly collaboration is expected to begin contributing in the fourth quarter, offering an early read on how these agreements translate into near-term results. As always, milestone timing will keep quarterly results variable.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations